Noninvasive cancer biomarkers are the alternatives for the invasive tissue biopsies used for the detection of tumor presence in various cancer types. These biomarkers are used for detecting the state of disease. There are various types of biomarkers available such as circulation tumor DNA, serum micro RNAs, DNA methylation based biomarker, and protein based biomarkers and others. The technology has made it possible these days for the healthcare industry to develop early diagnostics, at-risk tests as well as prognostic biomarkers for various cancer types. The advent of next generation sequencing and enhanced knowledge on genomics and proteomics has promoted the use of noninvasive cancer biomarkers. Advancement in noninvasive cancer biomarkers opens new possibilities in the cancer treatment such as improving the therapeutic response, assessing the residues in the body, early diagnosis, measuring tumor heterogeneity and others. Increasing molecular characterization of different types of cancer also led to the increase in molecular drivers for cancer progression.
As more importance is being given nowadays on cancer prevention via early detection, the demand of these biomarkers is going to surge over the forecast period.
Several advantages of noninvasive cancer biomarkers over the invasive biopsies supports the growth of market. Continuous research in the area, development of new biomarkers and increasing prevalence of cancer cases worldwide is driving the global market. Furthermore, improvement in diagnostic facilities as well as increased access of these facilities also fuels the overall noninvasive cancer biomarkers market. Certain standardization issues with the use of these biomarkers, low concentration, lack of reliability, high cost of kits etc. contributes in restricting the market growth.
Increased cancer occurrence rate and development in the diagnosis and treatment is creating the market for noninvasive cancer biomarkers. Moreover, increased funding by various government as well as non-government organization in the oncology segment also supports the overall market. Availability of large number of kits in the market and the marketing strategies used by various manufacturers is creating competitive environment for the noninvasive cancer biomarkers market. Continuous research in this field also deepens the molecular understanding of cancer which increases the availability of biomarkers in the market.
Geographically, the market for Noninvasive Cancer Biomarkers can be segmented into five regions, North America, Latin America, Europe, Asia Pacific and Middle East & Africa. With large number of research and diagnostic laboratories as well as healthcare facilities, North America holds the largest market for the usage of these noninvasive cancer biomarkers for disease diagnosis and prognosis. This is followed by Europe with increasing academic as well as bio-pharmaceutical research activities and the advancement in healthcare facilities. Asia-Pacific is expected to be the growing market for the noninvasive cancer biomarkers because of increasing prevalence of different types of cancers and along with this, government support in the availability of healthcare facilities also supports the growth over the region.
Some major key players of Noninvasive Cancer Biomarkers market include Abbott Laboratories, Sino Biological Inc., Thermo fisher Scientific, Bio-Rad Laboratories, Inc., Merck KGaA, F. Hoffmann-La Roche Ltd. and many more.
A sample of this report is available upon request @ https://www.persistencemarketresearch.com/samples/17434